MSD Enters into Exclusive Global License for LM-299, An …
1 day ago · RAHWAY, N.J., November 14, 2024 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA) and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage …
Merck Enters into Exclusive Global License for LM-299, An ...
1 day ago · Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately held clinical-stage biotechnology company, today …
Merck Enters into Exclusive Global License for LM-299, An ...
1 day ago · LaNova is also eligible to receive up to $2.7 billion in milestone payments associated with the technology transfer, development, regulatory approval and commercialization of LM …
Merck signs up to $3.3 bln cancer drug deal with China-based LaNova
1 day ago · The deal allows Merck to take over development of LaNova's LM-299, a drug candidate targeting a protein called PD-1, which prevents the immune system from killing …
Merck Expands Oncology Pipeline By Securing License For LaNova ...
1 day ago · "This agreement adds to Merck's growing oncology pipeline and we look forward to advancing LM-299 with speed and rigor for patients in need," said Dean Y. Li, president, …
Merck in Cancer Licensing Pact With LaNova Medicines
23 hours ago · Merck on Thursday said it has secured an exclusive global license to develop, manufacture and commercialize LM-299, an investigational PD-1/VEGF bispecific antibody …
LaNova Medicines Announces Initiation of Phase 1 Clinical Trial of …
Oct 18, 2024 · LM-299 is a bispecific antibody developed by LaNova that targets both PD-1 and VEGF. This innovative therapy can simultaneously block the PD-1/PD-L1 and VEGF/VEGFR …
Merck Licenses LM-299, An Investigational Anti-PD-1/VEGF …
1 day ago · Under the agreement, LaNova has granted Merck an exclusive global license to develop, manufacture and commercialize LM-299. LaNova will receive an upfront payment of …
MSD joins PD-1/VEGF push in cancer with LaNova deal
23 hours ago · Now, the company has made a move to try to make sure it isn't left behind. Its solution is a licensing deal with Chinese biotech LaNova Medicines for LM-299, which consists …
Merck pays $588M for bispecific to defend Keytruda’s kingdom …
1 day ago · The Chinese put itself on the map last month when it disclosed the start of a phase 1 advanced solid tumor trial of its bispecific, LM-299, in China and a $42 million financing round. …
- Some results have been removed